Fixing the Economics of Antibiotic Development—Before It’s Too Late

2:00 PM - 2:45 PM (EDT), Monday, June 14, 2021
Search General Info
Search Education
Search Partnering Companies
Think the idea of another infectious disease pandemic sounds scary? If we don’t develop new antibiotics—quickly—antibiotic-resistant bacteria could kill as many as 10 million people PER YEAR by 2050.

Governments, the healthcare industry, and the media have been sounding the alarm about antimicrobial resistance, or AMR—and the urgent need to develop new antibotics to combat it. While there has been some policy movement to promote antibiotic innovation, the market remains challenging and antibiotic-focused biotechs have few opportunities for partnership and co-investment.

Two promising developments could address this: the AMR Action Fund, a pharma-led fund that will invest over $1 billion to bring 2-4 new antibiotics to market over the next 10 years, and the PASTEUR Act, a bipartisan bill that would establish a value-based subscription-style model for novel antibiotics.

During this session, hear from U.S. Sen. Michael Bennet (D-CO), one of the PASTEUR Act sponsors, and AMR Action Fund CEO Dr. Henry Skinner, along with leading antibiotic developers. They’ll discuss what is needed to accelerate development of novel antibiotics—before it’s too late.
Speaker
photo
CEO
AMR Action Fund